Literature DB >> 21252084

A randomised placebo-controlled trial of topical steroid in presumed viral conjunctivitis.

Mark R Wilkins1, Sharmina Khan, Catey Bunce, Anthony Khawaja, Dilani Siriwardena, Daniel F P Larkin.   

Abstract

AIMS: To assess whether topical steroids improve patient comfort compared with hypromellose in acute presumed viral conjunctivitis.
METHODS: Patients presenting with acute follicular conjunctivitis, presumed viral in origin, were randomised to receive either dexamethasone 0.1% or hypromellose 0.3% drops four times daily for 1 week. At review after 5-7 days patients completed questionnaires on whether they thought the treatment had helped and on their level of discomfort. A physician assessed conjunctival hyperaemia using a grading scale.
RESULTS: 111 patients were randomised: 56 received dexamethasone drops and 55 received hypromellose lubricant drops. Eighty-eight returned for review. Most patients (39/45 (87%)) receiving dexamethasone and most of those receiving hypromellose 30/43 (70%) felt that the treatment helped. Analysis of all responses showed a significant difference between treatments (p=0.0248, rank sum test). No significant differences between dexamethasone and hypromellose arms were found in the patients' perceived level of discomfort or the physician grading of conjunctival hyperaemia. No patient experienced a serious complication.
CONCLUSIONS: There us now evidence to support the use of a short course of topical dexamethasone for patients presenting with acute follicular conjunctivitis presumed to be viral in origin. Where topical dexamethasone is prescribed we have not found it to be harmful. TRIAL REGISTRATION: http://www.controlled-trials.com/ISRCTN50728656.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21252084     DOI: 10.1136/bjo.2010.188623

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  9 in total

1.  Comparison of clinical outcome with different treatment regimens in acute adenoviral keratoconjunctivitis.

Authors:  L Asena; E Şıngar Özdemir; A Burcu; E Ercan; M Çolak; D D Altınörs
Journal:  Eye (Lond)       Date:  2017-02-03       Impact factor: 3.775

2.  Cyclosporine in ocular surface inflammation.

Authors:  P Hossain
Journal:  Eye (Lond)       Date:  2017-02-17       Impact factor: 3.775

3.  Multi-parametric evaluation of ocular surface disorders during healing process of viral conjunctivitis.

Authors:  Gozde Sahin Vural; Ozlem Barut Selver; Ali Veral; Melis Palamar
Journal:  Int Ophthalmol       Date:  2021-11-29       Impact factor: 2.031

Review 4.  Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis.

Authors:  Su-Hsun Liu; Barbara S Hawkins; Sueko M Ng; Mark Ren; Louis Leslie; Genie Han; Irene C Kuo
Journal:  Cochrane Database Syst Rev       Date:  2022-03-03

5.  Determinants of Outcomes of Adenoviral Keratoconjunctivitis.

Authors:  Cecilia S Lee; Aaron Y Lee; Lakshmi Akileswaran; David Stroman; Kathryn Najafi-Tagol; Steve Kleiboeker; James Chodosh; Amalia Magaret; Anna Wald; Russell N Van Gelder
Journal:  Ophthalmology       Date:  2018-03-27       Impact factor: 12.079

Review 6.  Mystery eye: Human adenovirus and the enigma of epidemic keratoconjunctivitis.

Authors:  Rahul A Jonas; Lawson Ung; Jaya Rajaiya; James Chodosh
Journal:  Prog Retin Eye Res       Date:  2019-12-28       Impact factor: 21.198

7.  The effect of eye care protocol on the prevention of ocular surface disorders in patients admitted to intensive care unit.

Authors:  Fariba Mobarez; Neda Sayadi; Simin Jahani; Asaad Sharhani; Mohsen Savaie; Fereydoun Farrahi
Journal:  J Med Life       Date:  2022-08

8.  Comparative study on the efficacy of non-steroidal, steroid and non-use of anti-inflammatory in the treatment of acute epidemic conjunctivitis.

Authors:  Luiz Alfredo Santiago; Jussara Matyelle Rodrigues da Silva; Orleâncio Gomes Ripardo de Azevedo; Paulo Roberto Leitão de Vasconcelos
Journal:  Acta Cir Bras       Date:  2020-02-07       Impact factor: 1.388

9.  Content validity of a novel patient-reported and observer-reported outcomes assessment to evaluate ocular symptoms associated with infectious conjunctivitis in both adult and pediatric populations.

Authors:  Sujata P Sarda; Marie De La Cruz; Emuella M Flood; Magdalena Vanya; David G Hwang; Christopher N Ta; Abhijit Narvekar
Journal:  Health Qual Life Outcomes       Date:  2019-10-30       Impact factor: 3.186

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.